Contract analysis

1. Dormancy Status Pursuant to instruction received from Lisa Moritani, Esq., General Counsel and Corporate Secretary of Penterra Pharmaceuticals Corp. ("Penterra" or "PPC"), by email dated December 1, 2022, Matter No. 1018-00005 is hereby placed on dormant status effective December 1, 2022. The client in this matter is Penterra Pharmaceuticals Corp., a corporation organized and existing under the laws of the State o

2. Financial Summary The following table sets forth a comprehensive financial reconciliation for the engagement through the effective date of dormancy. All figures have been confirmed with the Firm's Finance Department as of the date of this memorandum and reflect all time entries, invoices, and payments processed through November 30, 2022. The billing arrangement for this matter, as set forth in the engagement lette

3. Staffing Record The following timekeepers billed to Matter No. 1018-00005 during the active engagement period (July 7, 2022 through November 30, 2022): No additional attorneys, of-counsel, paralegals, or other professional staff were assigned to this matter during the active engagement period. All substantive work was performed by the four timekeepers identified above. Joel Strauss served as the primary relationsh

4. File Preservation — Inventory of Work Product All physical and electronic files for Matter No. 1018-00005 are to be preserved in accordance with the Firm's document retention policy (most recently updated October 2021) and the client's specific preservation instruction, as communicated in the December 1, 2022 email from Lisa Moritani directing that all work product and correspondence be retained by the Firm pendin

5. Key Matter Context for Future Reference The following summary is provided to assist any future attorney reviewing this file upon reactivation of the matter. This section is intended as a reference overview and does not constitute legal advice or a comprehensive analysis of the regulatory issues involved. The memoranda and correspondence listed in Section 4 should be consulted for detailed analysis. 5.1 The Drug an

6. Reactivation Protocol Upon receipt of written notice from the client — specifically from Lisa Moritani, Esq., General Counsel and Corporate Secretary of Penterra Pharmaceuticals Corp., or her successor or designee — to reactivate Matter No. 1018-00005, the following steps will be taken: 6.1 Staffing Confirmation The responsible partner (Joel Strauss) will confirm staffing availability for the reactivated engagemen

7. Annual Dormancy Review Pursuant to the Firm's standard policy governing dormant matters (as set forth in the Calderwood & Harkness LLP Matter Management Policy, Section 8.4), dormant matters are reviewed annually to determine whether the matter should (a) remain on dormant status, (b) be reactivated, or (c) be formally closed. This annual review is the responsibility of the billing partner. This matter will be rev

8. Distribution and Filing This memorandum is to be filed in the electronic matter file for 1018-00005 on the Firm's document management system. The memorandum should be filed under the "Administration" document category within the matter workspace and should be tagged with the keywords "dormancy," "file preservation," and "matter administration" to facilitate future retrieval. Copies of this memorandum have been dis